Moderna (NASDAQ:MRNA) Price Target Lowered to $59.00 at JPMorgan Chase & Co.

Moderna (NASDAQ:MRNA) had its price target reduced by stock analysts at JPMorgan Chase & Co. from $70.00 to $59.00 in a report released on Monday, Benzinga reports. The brokerage currently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 7.43% from the company’s previous close.

A number of other analysts have also weighed in on MRNA. Leerink Partners lowered their target price on Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a report on Tuesday, September 17th. Barclays decreased their price objective on Moderna from $155.00 to $125.00 and set an “overweight” rating for the company in a research note on Monday, September 16th. UBS Group cut their target price on Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Jefferies Financial Group decreased their price target on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research report on Tuesday, October 15th. Finally, Oppenheimer downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a research report on Friday, September 13th. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $94.00.

Moderna Stock Up 0.5 %

Shares of MRNA stock traded up $0.29 on Monday, hitting $54.92. The stock had a trading volume of 685,744 shares, compared to its average volume of 4,331,185. Moderna has a one year low of $52.26 and a one year high of $170.47. The business has a 50 day moving average price of $64.61 and a 200 day moving average price of $100.99. The company has a market cap of $21.11 billion, a PE ratio of -3.53 and a beta of 1.69. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. During the same quarter in the previous year, the business posted ($3.62) EPS. The company’s quarterly revenue was down 29.9% compared to the same quarter last year. Research analysts anticipate that Moderna will post -9.88 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,184 shares of company stock worth $238,531 over the last 90 days. 15.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Moderna

A number of hedge funds have recently bought and sold shares of MRNA. Privium Fund Management B.V. raised its stake in shares of Moderna by 74.0% during the 3rd quarter. Privium Fund Management B.V. now owns 40,482 shares of the company’s stock worth $2,705,000 after buying an additional 17,221 shares during the period. SpiderRock Advisors LLC raised its position in Moderna by 1,442.5% during the third quarter. SpiderRock Advisors LLC now owns 26,917 shares of the company’s stock worth $1,799,000 after acquiring an additional 25,172 shares during the period. AIA Group Ltd lifted its holdings in Moderna by 12.2% during the third quarter. AIA Group Ltd now owns 16,291 shares of the company’s stock valued at $1,089,000 after purchasing an additional 1,765 shares in the last quarter. ARK Investment Management LLC lifted its holdings in Moderna by 10.4% during the third quarter. ARK Investment Management LLC now owns 1,163,946 shares of the company’s stock valued at $77,787,000 after purchasing an additional 109,852 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of Moderna by 4.2% during the third quarter. Principal Financial Group Inc. now owns 379,451 shares of the company’s stock worth $25,359,000 after purchasing an additional 15,218 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.